GLGuanjing Ling

Guanjing Ling

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guanjing Ling has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Yawen Zhang

    5 shared publications
  • Yong Wang

    Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100029, China; School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China; Beijing Key Laboratory of TCM Syndrome and Formula, Beijing University of Chinese Medicine, Beijing 100029, China; Key Laboratory of TCM Syndrome and Formula (Beijing University of Chinese Medicine), Ministry of Education, Beijing 100029, China

    5 shared publications
  • Jinchi Jiang

    School of Chinese Medicine

    4 shared publications
  • Xiaoping Wang

    College of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China; Department of Pathophysiology, State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100005, China

    4 shared publications
  • Nannan Tan

    School of Chinese Medicine

    3 shared publications
  • Qianbin Sun

    School of Life Sciences

    3 shared publications

Latest Publications

  • Open Access

    Anthracycline-induced cardiotoxicity: emerging mechanisms and therapies

    by Guanjing Ling, Fei Ge, Weili Li, Yan Wei, Shujuan Guo, Yuqin Zhang, Yilin Li, Yawen Zhang, Heng Liu, Yunxia Wu, et al.


  • Activation of ULK1 to trigger FUNDC1-mediated mitophagy in heart failure: Effect of Ginsenoside Rg3 intervention

    by Xiaoping Wang, Guanjing Ling, Yan Wei, Weili Li, Yawen Zhang, Nannan Tan, Wei Li, Haijing Li, Qi Qiu, Wei Wang, et al.


  • Open Access

    Mechanisms and Drug Intervention for Doxorubicin‐Induced Cardiotoxicity Based on Mitochondrial Bioenergetics

    by Guanjing Ling, Xiaoping Wang, Nannan Tan, Jing Cao, Weili Li, Yawen Zhang, Jinchi Jiang, Qianbin Sun, Yanyan Jiang, Wei Wang, et al.

    Doxorubicin (DOX) is an anthracycline chemotherapy drug, which is indispensable in antitumor therapy. However, its subsequent induction of cardiovascular disease (CVD) has become the primary cause of mortality in cancer survivors. Accumulating evidence has demonstrated that cardiac mitochondrial bioenergetics changes have become a significant marker for doxorubicin‐induced cardiotoxicity (DIC). Here, we mainly summarize the related mechanisms of DOX‐induced cardiac mitochondrial bioenergetics disorders reported in recent years, including mitochondrial substrate metabolism, the mitochondrial respiratory chain, myocardial ATP storage and utilization, and other mechanisms affecting mitochondrial bioenergetics. In addition, intervention for DOX‐induced cardiac mitochondrial bioenergetics disorders using chemical drugs and traditional herbal medicine is also summarized, which will provide a comprehensive process to study and develop more appropriate therapeutic strategies for DIC.


  • Open Access

    Effects and Safety of Oral Iron for Heart Failure with Iron Deficiency: A Systematic Review and Meta-Analysis with Trial Sequential Analysis

    by Nannan Tan, Yiqing Cai, Junjie Liu, Xiaoping Wang, Lin Ma, Guanjing Ling, Jinchi Jiang, Qiyan Wang, Yong Wang

    Effects and Safety of Oral Iron for Heart Failure with Iron Deficiency: A Systematic Review and Meta-Analysis with Trial Sequential Analysis: Background. Oral iron supplement is commonly prescribed to heart failure patients with iron deficiency. However, the effects of oral iron for heart failure remain controversial. This study included randomized controlled trials (RCTs) for meta-analysis to evaluate the effects of oral iron for heart failure patients. Methods. Nine databases (The Cochrane Library, Embase, PubMed, CINAHL, Web of science, CNKI, SinoMed, VIP, and Wanfang) were searched for RCTs of oral iron for heart failure from inception to October 2021. The effects were assessed with a meta-analysis using Revman 5.3 software. The trial sequential analysis was performed by TSA 0.9.5.10 beta software. The risk of bias of trials was evaluated via Risk of Bias tool. The evidence quality was assessed through GRADE tool. Results. Four studies including 582 patients with heart failure and iron deficiency were enrolled. The results indicated that oral iron treatment could improve left ventricular ejection fraction (LVEF, , 95% CI: 0.69 to 2.36, ) and serum ferritin ( , 95% CI: 0.26 to 3.02, ). However, there was no between-group difference in the 6-minute walk distances (6MWT), N terminal pro B type natriuretic peptide (NT-proBNP) or hemoglobin level when compared with control group. Subgroup analyses revealed that the effects of oral iron on 6 MWT and serum ferritin could not be affected by duration and frequency of oral iron uptakes. In trial sequential analysis of LVEF and serum ferritin, the Z-curves crossed the traditional boundary and trail sequential monitoring boundary but did not reach the required information size. Conclusion. This analysis showed that oral iron could improve cardiac function measured by LVEF, and iron stores measured serum ferritin, but lack of effect on exercise capacity measured by 6 MWT, and iron stores measured by hemoglobin. Given the overall poor methodological quality and evidence quality, these findings should be treated cautiously.


  • Open Access

    Qishen Granule Protects against Doxorubicin‐Induced Cardiotoxicity by Coordinating MDM2‐p53‐Mediated Mitophagy and Mitochondrial Biogenesis

    by Weili Li, Yawen Zhang, Xiaoping Wang, Jing Cao, Weina Qian, Guanjing Ling, Nannan Tan, Jinchi Jiang, Qianbin Sun, Chun Li, et al.

    Doxorubicin (DOX), the anthracycline chemotherapeutic agent, is widely used for the treatment of various cancers. However, its clinical application is compromised by dose‐dependent and fatal cardiotoxicity. This study is aimed at investigating the cardioprotective effects of Qishen granule (QSG) and the specific mechanism by which QSG alleviates DOX‐induced cardiotoxicity (DIC) and providing an alternative for the treatment of DIC. We first evaluated the cardioprotective effects of QSG in a DIC mouse model, and the obtained results showed that QSG significantly protected against DOX‐induced myocardial structural and functional damage, mitochondrial oxidative damage, and apoptosis. Subsequently, after a comprehensive understanding of the specific roles and recent developments of p53‐mediated mitochondrial quality control mechanisms in DIC, we investigated whether QSG acted on MDM2 to regulate the activity of p53 and downstream mitophagy and mitochondrial biogenesis. The in vivo results showed that DOX inhibited mitochondrial biogenesis and blocked mitophagy in the mouse myocardium, while QSG reversed these effects. Mechanistically, we combined nutlin‐3, which inhibits the binding of p53 and MDM2, with DOX and QSG and evaluated their influence on mitophagy and mitochondrial biogenesis in H9C2 cardiomyocytes. The obtained results showed that both DOX and nutlin‐3 substantially inhibited mitophagy and mitochondrial biogenesis and induced mitochondrial oxidative damage and apoptosis, which could be partially recovered by QSG. Importantly, the immunoprecipitation results showed that QSG promoted the binding of MDM2 to p53, thus decreasing the level of p53 protein and the binding of p53 to Parkin. Collectively, QSG could promote the degradation of p53 by enhancing the binding of MDM2 to the p53 protein, resulting in the reduced binding of p53 to the Parkin protein, thus improving Parkin‐mediated mitophagy. Increased degradation of p53 protein by QSG simultaneously enhanced mitochondrial biogenesis mediated by PGC‐1α. Ultimately, QSG relieved DOX‐induced mitochondrial oxidative damage and apoptosis by coordinating mitophagy and mitochondrial biogenesis.


  • Open Access

    The roles of the mitophagy inducer Danqi pill in heart failure: A new therapeutic target to preserve energy metabolism

    by Xiaoping Wang, Yanyan Jiang, Yawen Zhang, Qianbin Sun, Guanjing Ling, Jinchi Jiang, Weili Li, Xue Tian, Qianqian Jiang, Linghui Lu, et al.